Source Count: 9 | Weighted Score: 19 | Source Confidence: [2/5] | Primary Tier: 2 | Last Updated: March 11, 2026
Keywords: microdosing, sub-perceptual, LSD, psilocybin, creativity, cognitive enhancement, Silicon Valley, placebo, psychedelics, nootropics
Category Tags: altered-states, psychedelics, cognition, creativity, pharmacology
Cross-References: Y_1_04 — LSD · Y_1_01 — Psilocybin · T_3_02 — Creativity

QUICK SUMMARY

Micro-dosing — the practice of regularly consuming sub-perceptual doses (typically 1/10th to 1/20th of a standard recreational dose) of psychedelic substances, most commonly LSD (~10–20 micrograms) or psilocybin (~0.1–0.3 grams of dried mushrooms) — emerged as a widely discussed phenomenon in the 2010s, particularly after James Fadiman's The Psychedelic Explorer's Guide (2011) popularized the concept and Ayelet Waldman's A Really Good Day (2017) brought it mainstream attention. The practice became especially associated with Silicon Valley tech culture, where micro-dosing was promoted as a cognitive enhancement strategy — claimed to improve creativity, focus, emotional balance, and productivity without the perceptual distortions and impairment of full psychedelic doses. The scientific evidence remains mixed and contested: large-scale naturalistic surveys (Polito and Stevenson, 2019; Anderson et al., 2019) consistently find that micro-dosers report subjective improvements in mood, creativity, and openness, but the first rigorous placebo-controlled studies (Yanakieva et al., 2019; Szigeti et al., 2021) have produced far less clear-cut results — with the placebo condition producing effects nearly as large as the active drug condition, suggesting that expectancy effects (placebo) account for a substantial portion of reported benefits. The question of whether micro-dosing produces genuine pharmacological effects beyond placebo remains one of the most actively debated topics in contemporary psychedelic science.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

1.1 What Micro-Dosing Is

• Definition: the regular (typically every 3rd or 4th day — the "Fadiman protocol") consumption of psychedelic substances at doses below the perceptual threshold — meaning the user should not experience obvious perceptual changes (no visual distortions, no significant altered state); the dose is intended to produce subtle cognitive, emotional, or creative effects while remaining functional for normal daily activities
• Common substances: LSD (10–20 µg — a standard recreational dose is 100–200 µg); psilocybin mushrooms (0.1–0.3 g dried — a standard dose is 2–5 g); less commonly, 1P-LSD, mescaline, DMT, or synthetic tryptamines
• Protocols: Fadiman protocol (1 day on, 2 days off); Stamets protocol (4 days on, 3 days off, often combined with lion's mane mushroom and niacin); various individualized schedules

1.2 Naturalistic Survey Data

• Polito and Stevenson (2019): prospective longitudinal study — 98 micro-dosers tracked for 6 weeks; reported decreased depression, decreased mind-wandering, increased absorption, increased openness — but these were self-selected, unblinded participants
• Anderson et al. (2019): large online survey — micro-dosers reported greater creativity, openness, and wisdom, and lower dysfunctional attitudes and negative emotionality than non-micro-dosing controls; BUT volunteers were self-selected and unblinded
• Consistent finding across surveys: micro-dosers consistently report subjective benefits — improved mood, focus, creativity, social interaction, and reduced anxiety and depression

1.3 Placebo-Controlled Studies

• Yanakieva et al. (2019): double-blind, placebo-controlled study of micro-dose LSD — found that micro-doses altered time perception (overproduction of temporal intervals — subjective time felt slower) but did not significantly improve measures of cognition, creativity, or mood compared to placebo
• Szigeti et al. (2021): ingenious "self-blinding" study — participants prepared their own capsules (active micro-dose or placebo) with QR codes for unblinding; N=191; found that micro-dosing produced significant improvements in well-being, mindfulness, and life satisfaction — BUT placebo produced improvements of nearly equal magnitude; no significant difference between active and placebo conditions
• This is the strongest evidence to date that expectancy/placebo effects account for most of the reported benefits of micro-dosing

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 Potential Genuine Pharmacological Effects

• At 10–20 µg, LSD does have measurable pharmacological effects: serotonin 5-HT2A receptor binding, altered default mode network activity (potentially), subtle changes in neural oscillatory patterns — the question is whether these sub-threshold neural changes produce functionally meaningful cognitive or emotional improvements
• Family et al. (2020): micro-dose LSD (5, 10, and 20 µg) altered aspects of temporal cognition and emotional processing (reduced recognition of fearful faces) in a dose-dependent manner — suggesting genuine pharmacological effects even at sub-perceptual doses
• Hutten et al. (2020): systematic review concluded that while there is some evidence for subtle cognitive and emotional effects of micro-doses, the evidence base remains preliminary and heavily contaminated by expectation effects

2.2 The Silicon Valley Narrative

• Micro-dosing became a widely reported cultural phenomenon in the mid-2010s, particularly associated with the San Francisco/Silicon Valley tech community — promoted by figures like Tim Ferriss, featured in Rolling Stone (2015), Wired, The New York Times, and numerous podcasts
• The cultural narrative framed micro-dosing as a productivity hack — analogous to nootropics, Modafinil, or meditation — rather than as a psychedelic/spiritual practice; this reframing helped normalize psychedelic use among professional demographics

2.3 Risks and Concerns

• Cardiovascular risk: LSD and psilocybin are 5-HT2B agonists; chronic 5-HT2B agonism (as with fenfluramine) has been associated with valvular heart disease — the risk of micro-dosing at low doses over extended periods is unknown but theoretically concerning
• Legal status: LSD and psilocybin remain Schedule I substances in most jurisdictions — micro-dosing involves illegal drug possession in most countries

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Micro-Dosing as Genuine Cognitive Enhancer

• The claim that micro-dosing reliably enhances creativity, problem-solving, or cognitive performance beyond placebo remains unproven — while plausible given the known neuroplasticity-promoting effects of psychedelic substances (BDNF upregulation, increased dendritic spine density), current evidence cannot distinguish genuine pharmacological enhancement from expectancy effects in most domains

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 Micro-Dosing as Risk-Free Panacea

• [MISLEADING] Claims that micro-dosing is completely safe, has no side effects, and can replace conventional treatments for depression, ADHD, anxiety, etc. — long-term safety data are lacking; cardiac risks are theoretical but not excluded; micro-dosing should not replace evidence-based treatments; individual responses vary significantly

Counter-Arguments & Criticisms

Psychedelic microdosing research has produced mixed results challenging popular claims. Szigeti et al. (2021), in the first large randomized controlled trial using a self-blinding citizen science design, found that microdosing effects did not exceed placebo, suggesting expectancy and confirmation bias explain reported benefits. Petranker et al. (2020) noted that the microdosing community’s self-reports are subject to selection bias and demand characteristics. Concerns about cardiac valve risks from chronic serotonin 2B receptor agonism with psilocybin and LSD microdosing have been raised (Wacker et al., 2013). Anderson et al. (2019) found self-reported benefits in an open-label study but acknowledged the absence of placebo control. The legal status of microdosing substances in most jurisdictions creates additional research barriers and ethical concerns.

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Fadiman, James | 2011 | ∅ | The Psychedelic Explorer's Guide | ∅ | ∅ | Rochester: Park Street Press | ∅ | isbn:9781594774027 | ∅ | ∅ | ∅
2. Polito, Vince; Richard J | 2019 | "A Systematic Study of Microdosing Psychedelics" | PLoS ONE | ∅ | 14.2:: | Stevenson. e0211023 | ∅ | doi:10.1371/journal.pone.0211023 | ∅ | ∅ | ∅
3. Anderson, Thomas, et al | 2019 | "Microdosing Psychedelics: Personality, Mental Health, and Creativity Differences in Microdosers" | Psychopharmacology | ∅ | 236.2::731–740 | ∅ | ∅ | doi:10.1007/s00213-018-5106-2 | ∅ | ∅ | ∅
4. Szigeti, Balázs, et al. e62878 | 2021 | "Self-Blinding Citizen Science to Explore Psychedelic Microdosing" | eLife | ∅ | 10:: | ∅ | ∅ | doi:10.7554/elife.62878 | ∅ | ∅ | ∅
5. Yanakieva, Steliana, et al | 2019 | "The Effects of Microdose LSD on Time Perception" | Psychopharmacology | ∅ | 236.4::1159–1170 | ∅ | ∅ | doi:10.1007/s00213-018-5119-x | ∅ | ∅ | ∅
6. Waldman, Ayelet | 2017 | ∅ | A Really Good Day: How Microdosing Made a Mega Difference in My Mood, My Marriage, and My Life | ∅ | ∅ | New York: Knopf | ∅ | doi:10.1108/s0065-283020210000049018 | ∅ | ∅ | ∅
7. Family, Neiloufar, et al | 2020 | "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Low Dose Lysergic Acid Diethylamide (LSD) in Healthy Older Volunteers" | Psychopharmacology | ∅ | 237.5::1177–1189 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
8. Hutten, Natasha R | 2019 | "Motives and Side-Effects of Microdosing with Psychedelics Among Users" | International Journal of Neuropsychopharmacology | ∅ | 22.7::426–434 | P | ∅ | ∅ | ∅ | ∅ | W., et al
9. Kuypers, Kim P | 2020 | "Microdosing Psychedelics: More Questions Than Answers? An Overview and Suggestions for Future Research" | Journal of Psychopharmacology | ∅ | 34.9::968–977 | C | ∅ | ∅ | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: March 11, 2026